PSYENCE BIOMEDICAL LTD. (PBM) - Dilution Analysis

20-F filing | 0.6M shares outstanding

F-3 filing: This is an F-3 filing for Psyence Biomedical Ltd. registering up to $75,000,000 of various securities, an ATM offering of up to $2,591,260, and the potential resale of 311,374 Common Shares by Selling Securityholders.

F-1 filing: This is an F-1 filing describing the terms and conditions of warrants that can be exercised for common shares. The warrants have a redemption trigger price of US$1,350.00 per share and an exercise price of US$862.50. The company has the option to require cashless exercise of warrants. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to the Company, for the number of warrants being exercised.

F-1 filing: This F-1 filing discusses the resale of Common Shares by White Lion and other Selling Securityholders. White Lion has resold approximately 1,671,667 Common Shares and may sell up to an additional 333,333 Common Shares. The company may receive gross proceeds of up to $18,612,403 from the sale of Common Shares to White Lion pursuant to the White Lion Purchase Agreement.

F-1 filing: This F-1 filing registers common shares, including those issued to Psylabs and those that may be sold by selling securityholders, including White Lion, with potential proceeds of up to $21,638,500 million from sales to White Lion.

F-1 filing: This F-1 filing describes the potential sale of common shares by Selling Securityholders and the potential exercise of warrants, with the company not receiving proceeds from the share sales but potentially receiving proceeds from warrant exercises for general working capital purposes.

F-1 filing: This F-1 filing discusses the terms of warrants, including redemption criteria, exercise price adjustments, and cashless exercise options. It also mentions potential dividends, share splits, and reclassifications affecting the number of shares issuable upon warrant exercise.

POS AM filing: This is a POS AM filing for Psyence Biomedical Ltd. relating to the resale of common shares, warrants, and common shares underlying warrants.

20-F filing | 13.4M shares outstanding

F-1 filing: This F-1 filing outlines the expected expenses related to an offering, totaling $4,781.21, primarily consisting of the SEC registration fee.